CD8型
细胞毒性T细胞
效应器
免疫系统
生物
细胞生物学
免疫学
癌症免疫疗法
T细胞
免疫
癌症研究
调节器
免疫疗法
生物化学
基因
体外
作者
Lele Zhu,Xiaofei Zhou,Meidi Gu,Jiseong Kim,Yanchuan Li,Chun‐Jung Ko,Xiaoping Xie,Tianxiao Gao,Xuhong Cheng,Shao‐Cong Sun
标识
DOI:10.1038/s41556-022-00942-8
摘要
CD8+ T cells are central mediators of immune responses against infections and cancer. Here we identified Dapl1 as a crucial regulator of CD8+ T cell responses to cancer and infections. Dapl1 deficiency promotes the expansion of tumour-infiltrating effector memory-like CD8+ T cells and prevents their functional exhaustion, coupled with increased antitumour immunity and improved efficacy of adoptive T cell therapy. Dapl1 controls activation of NFATc2, a transcription factor required for the effector function of CD8+ T cells. Although NFATc2 mediates induction of the immune checkpoint receptor Tim3, competent NFATc2 activation prevents functional exhaustion of CD8+ T cells. Interestingly, exhausted CD8+ T cells display attenuated NFATc2 activation due to Tim3-mediated feedback inhibition; Dapl1 deletion rescues NFATc2 activation and thereby prevents dysfunction of exhausted CD8+ T cells in chronic infection and cancer. These findings establish Dapl1 as a crucial regulator of CD8+ T cell immunity and a potential target for cancer immunotherapy. Zhu et al. identify Dapl1 as a negative regulator of CD8+ T cell responses by modulating NFATc2 activation and T cell exhaustion, leading to dysregulated control of chronic infection and cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI